Literature DB >> 17593543

Ovarian failure in ataxia with oculomotor apraxia type 2.

David R Lynch1, Corey D Braastad, Narasimhan Nagan.   

Abstract

Ataxia with oculomotor apraxia type 2 (AOA2) is an autosomal recessive disorder associated with mutations in the Senataxin (SETX) gene. Clinical manifestations (ataxia, peripheral neuropathy, oculomotor apraxia) of this disease have previously been limited to the nervous system. We describe a patient homozygous for a novel mutation of SETX who manifested not only ataxia but also ovarian failure. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593543     DOI: 10.1002/ajmg.a.31816

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  14 in total

1.  Holmes-Like Tremor in Ataxia With Oculomotor Apraxia Type 2.

Authors:  Maria Chiara D'Amico; Iole Borrelli; Holta Zhuzhuni; Aurelio D'Amico; Roberta Di Giacomo; Luca Mancinelli; Valeria di Tommaso; Antonio Di Muzio; Marco Onofrj
Journal:  Mov Disord Clin Pract       Date:  2014-07-28

2.  Interpretation of genetic testing: variants of unknown significance.

Authors:  Brent L Fogel
Journal:  Continuum (Minneap Minn)       Date:  2011-04

3.  Disruption of Spermatogenesis and Infertility in Ataxia with Oculomotor Apraxia Type 2 (AOA2).

Authors:  Olivier J Becherel; Brent L Fogel; Scott I Zeitlin; Hemamali Samaratunga; Jessica Greaney; Hayden Homer; Martin F Lavin
Journal:  Cerebellum       Date:  2019-06       Impact factor: 3.847

4.  Characterization of two novel SETX mutations in AOA2 patients reveals aspects of the pathophysiological role of senataxin.

Authors:  Giovanni Airoldi; Andrea Guidarelli; Orazio Cantoni; Chris Panzeri; Chiara Vantaggiato; Sara Bonato; Maria Grazia D'Angelo; Sestina Falcone; Clara De Palma; Alessandra Tonelli; Claudia Crimella; Sara Bondioni; Nereo Bresolin; Emilio Clementi; Maria Teresa Bassi
Journal:  Neurogenetics       Date:  2009-07-11       Impact factor: 2.660

5.  Ataxia oculomotor apraxia type 2: course over 27 years and a novel stop mutation in the senataxin gene.

Authors:  Tobias Haack; Douglas Friday; Andreas Bender; Arndt Rolfs; Thomas Klopstock
Journal:  J Neurol       Date:  2009-04-18       Impact factor: 4.849

6.  A novel c.5308_5311delGAGA mutation in Senataxin in a Cypriot family with an autosomal recessive cerebellar ataxia.

Authors:  Paschalis Nicolaou; Anthi Georghiou; Christina Votsi; Lefkos T Middleton; Eleni Zamba-Papanicolaou; Kyproula Christodoulou
Journal:  BMC Med Genet       Date:  2008-04-14       Impact factor: 2.103

7.  An atypical form of AOA2 with myoclonus associated with mutations in SETX and AFG3L2.

Authors:  Cecilia Mancini; Laura Orsi; Yiran Guo; Jiankang Li; Yulan Chen; Fengxiang Wang; Lifeng Tian; Xuanzhu Liu; Jianguo Zhang; Hui Jiang; Bruce Shike Nmezi; Takashi Tatsuta; Elisa Giorgio; Eleonora Di Gregorio; Simona Cavalieri; Elisa Pozzi; Paolo Mortara; Maria Marcella Caglio; Alessandro Balducci; Lorenzo Pinessi; Thomas Langer; Quasar S Padiath; Hakon Hakonarson; Xiuqing Zhang; Alfredo Brusco
Journal:  BMC Med Genet       Date:  2015-03-19       Impact factor: 2.103

8.  Aberrant splicing of the senataxin gene in a patient with ataxia with oculomotor apraxia type 2.

Authors:  Brent L Fogel; Ji Yong Lee; Susan Perlman
Journal:  Cerebellum       Date:  2009-12       Impact factor: 3.847

9.  Senataxin mutations elicit motor neuron degeneration phenotypes and yield TDP-43 mislocalization in ALS4 mice and human patients.

Authors:  Craig L Bennett; Somasish G Dastidar; Shuo-Chien Ling; Bilal Malik; Travis Ashe; Mandheer Wadhwa; Derek B Miller; Changwoo Lee; Matthew B Mitchell; Michael A van Es; Christopher Grunseich; Yingzhang Chen; Bryce L Sopher; Linda Greensmith; Don W Cleveland; Albert R La Spada
Journal:  Acta Neuropathol       Date:  2018-05-03       Impact factor: 17.088

10.  Exon deletions and intragenic insertions are not rare in ataxia with oculomotor apraxia 2.

Authors:  Veronica Bernard; Martina Minnerop; Katrin Bürk; Friedmar Kreuz; Gabriele Gillessen-Kaesbach; Christine Zühlke
Journal:  BMC Med Genet       Date:  2009-09-11       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.